Legal Representation
Attorney
Daniel Chalker
USPTO Deadlines
Next Deadline
1727 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240924)
Due Date
September 24, 2030
Grace Period Ends
March 24, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 24, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 24, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 9, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 9, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 19, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 30, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 26, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 26, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 26, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 8, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 8, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 8, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 25, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 28, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 28, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 28, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 1, 2023 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Aug 18, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Aug 17, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 22, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Pharmaceutical peptide, protein, antibody, and chimeric antibody or protein drug development services; Pharmaceutical peptide, protein, antibody, and chimeric antibodies or proteins product development; Pharmaceutical research and development of peptides, proteins, antibodies, and chimeric antibodies or proteins; Conducting early evaluations in the field of new peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical preparations and medicines; Laboratory peptide and protein based research services relating to pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Research on the subject of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Technical research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical studies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff made with peptides, proteins, antibodies, and chimeric antibodies or proteins; Research and development in the pharmaceutical and biotechnology fields; Research and development regarding pharmaceuticals, proteins, and antibodies; platform-as-a-service (PaaS) featuring computer software platforms for protein analysis and discovery of antibody-based drugs; Software as a service (SAAS) services featuring software for designing molecule libraries for the purposes of generating products in the field of pharmaceuticals, biotechnology, and medicine; Computer software development in the field of artificial intelligence, biotechnology, pharmaceuticals, and medical applications; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing on-line non-downloadable software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Scientific research for medical purposes in the area of cancerous diseases; Software as a service (SAAS) services featuring software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Technical consulting in the field of pharmaceutical studies; Technology consultation in the field of artificial intelligence; Testing of pharmaceuticals; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical testing services and information in the field of cancer research and disease classification; Providing information about medical research in the field of artificial intelligence, medical biotechnology, and pharmaceuticals
First Use Anywhere:
Jul 11, 2023
First Use in Commerce:
Jul 11, 2023
Additional Information
Design Mark
The mark consists of stylized word "IBIO", with the dot in the second "I" in the form of a double helix forming an infinity image, with arrow images in the interior of one side of the infinity form, and an image of carbons inside the other side of the infinity image.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
042